Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and FibrosisThe present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and 4) angiogenesis. Small molecule agonists of RXFP1 may be useful in treating acute heart failure (AHF), scleroderma, fibrosis, other conditions associated with the biology of relaxin, and in improving reproductive health and wound healing. These compounds are the first and only small molecule agonists of RXFP1.
Source:
Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and FibrosisLinkback:
https://tubagbohol.mikeligalig.com/index.php?topic=65287.0
Topic: Science News: Novel Small Molecule Agonists of the Relaxin Receptor as Potential Therapy for Heart Failure and Fibrosis (Read 299 times)